Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs in Development, 2021

Global Markets Direct’s, ‘Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs in Development, 2021’, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen’s Disease)

– The report reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neurofibromatoses Type I (Von Recklinghausen’s Disease) therapeutics and enlists all their major and minor projects

– The report assesses Neurofibromatoses Type I (Von Recklinghausen’s Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

AlloMek Therapeutics

AstraZeneca Plc

Bristol-Myers Squibb Co

Eli Lilly and Co

Fochon Pharmaceutical Ltd

Healx Ltd

NFlection Therapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Sino Biopharmaceutical Ltd

SpringWorks Therapeutics Inc

Vyriad Inc

Table of Contents

Table of Contents

Introduction

Global Markets Direct Report Coverage

Neurofibromatoses Type I – Overview

Neurofibromatoses Type I – Therapeutics Development

Neurofibromatoses Type I – Therapeutics Assessment

Neurofibromatoses Type I – Companies Involved in Therapeutics Development

Neurofibromatoses Type I – Drug Profiles

Neurofibromatoses Type I – Dormant Projects

Neurofibromatoses Type I – Discontinued Products

Neurofibromatoses Type I – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Advenchen Laboratories LLC, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by AlloMek Therapeutics, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by AstraZeneca Plc, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Bristol-Myers Squibb Co, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Eli Lilly and Co, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Fochon Pharmaceutical Ltd, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Healx Ltd, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by NFlection Therapeutics Inc, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Novartis AG, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Ono Pharmaceutical Co Ltd, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Pfizer Inc, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Sino Biopharmaceutical Ltd, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by SpringWorks Therapeutics Inc, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Vyriad Inc, 2021

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports